The Fort Worth Press - MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

USD -
AED 3.672501
AFN 63.999821
ALL 82.253977
AMD 360.510128
ANG 1.790403
AOA 917.498737
ARS 1552.758602
AUD 1.483977
AWG 1.8025
AZN 1.699803
BAM 1.779545
BBD 2.01413
BDT 124.905034
BGN 1.77347
BHD 0.377331
BIF 3007.507166
BMD 1
BND 1.288858
BOB 11.66537
BRL 5.796998
BSD 1.000059
BTN 93.425596
BWP 13.998644
BYN 3.001178
BYR 19600
BZD 2.011401
CAD 1.429745
CDF 2317.999928
CHF 0.841035
CLF 0.02537
CLP 998.480068
CNY 6.66455
CNH 6.666355
COP 3314.81
CRC 445.481718
CUC 1
CUP 24.000873
CVE 100.328012
CZK 22.18105
DJF 178.098271
DKK 6.79992
DOP 60.559465
DZD 137.08899
EGP 53.689599
ERN 15
ETB 164.140883
EUR 0.90965
FJD 2.296797
FKP 0.758367
GBP 0.75805
GEL 2.595013
GGP 0.758367
GHS 11.73543
GIP 0.758367
GMD 73.502912
GNF 8860.460038
GTQ 7.643069
GYD 209.144677
HKD 7.846205
HNL 26.886001
HRK 6.831965
HTG 131.024035
HUF 333.008502
IDR 18270.5
ILS 3.24803
IMP 0.758367
INR 93.48355
IQD 1516.079284
IRR 1925253.999459
ISK 124.44977
JEP 0.758367
JMD 158.919789
JOD 0.708989
JPY 159.399503
KES 129.999947
KGS 87.449019
KHR 4080.072793
KMF 447.497235
KPW 900.00035
KRW 1336.402706
KWD 0.31172
KYD 0.833458
KZT 444.016797
LAK 22523.690592
LBP 89554.848894
LKR 332.782835
LRD 168.006442
LSL 16.919297
LTL 2.95274
LVL 0.60489
LYD 6.462884
MAD 9.981438
MDL 18.311519
MGA 4549.44565
MKD 56.069019
MMK 2099.8229
MNT 3605.49036
MOP 8.082545
MRU 40.524838
MUR 47.859893
MVR 15.409893
MWK 1734.212921
MXN 18.486875
MYR 4.094503
MZN 63.910141
NAD 16.918528
NGN 1349.369821
NIO 36.80602
NOK 9.625225
NPR 149.481136
NZD 1.81936
OMR 0.384508
PAB 1.000032
PEN 3.415635
PGK 4.499381
PHP 63.6585
PKR 276.505202
PLN 4.00316
PYG 6230.864068
QAR 3.64562
RON 4.865802
RSD 107.022012
RUB 82.04668
RWF 1480.116648
SAR 3.756442
SBD 8.098361
SCR 13.879028
SDG 601.49862
SEK 10.126925
SGD 1.288895
SHP 0.758581
SLE 23.050416
SLL 20969.503664
SOS 571.501363
SRD 37.43798
STD 20697.981008
STN 22.292284
SVC 8.750364
SYP 13002.000337
SZL 16.918877
THB 33.834502
TJS 9.216015
TMT 3.51
TND 3.026264
TOP 2.40776
TRY 50.417602
TTD 6.771395
TWD 32.941978
TZS 2650.003004
UAH 45.33545
UGX 4149.985442
UYU 40.627659
UZS 12019.053598
VES 914.603604
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 596.691317
XAG 0.02097
XAU 0.000259128447
XCD 2.70255
XCG 1.802383
XDR 0.707052
XOF 596.691317
XPF 108.509428
YER 236.503383
ZAR 16.94351
ZMK 9001.198726
ZMW 20.486504
ZWL 321.999592
SSP 5946.953244
MXV 2.073939
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Ketamir-2, its novel oral ketamine analog for the treatment of neuropathic pain. The IND submission marks a major step in advancing Mira's lead drug candidate while reflecting its commitment to meeting milestones and timelines.

Text size:

Erez Aminov, Chairman & CEO of Mira, stated: "This IND submission highlights our team's commitment to executing efficiently as we advance transformative therapies. Ketamir-2 not only has demonstrated remarkable potential for neuropathic pain but also offers a broad opportunity across other major neuropsychiatric conditions. We look forward to beginning Phase I trials and continuing to deliver on our mission to address unmet medical needs."

The IND application includes comprehensive data and reports detailing Ketamir-2's pharmacology, pharmacokinetics, and toxicology, along with results from both in vitro and in vivo studies, including validated neuropathic pain disease models. In parallel with the submission, the company is preparing to conduct a complementary neurotoxicity study, as required by the FDA's written feedback to the pre-IND documentation.

According to a market analysis report from Fortune Business Insights, the neuropathic pain market in North America, including the United States, Canada, and Mexico, is valued at $3.1 billion and is expected to grow at a 6-7% compound annual growth rate (CAGR), reaching $4.5 billion by 2030. Despite this growth, existing treatments remain inadequate. Gabapentin and pregabalin, while widely prescribed, provide limited efficacy and are associated with side effects such as sedation, dizziness, and weight gain. Opioids remain a common treatment option but come with well-known risks of dependency, addiction, and respiratory depression. Intravenous ketamine, though effective for some patients, requires invasive administration and is often associated with psychotropic side effects, including hallucinations and dissociation.

Ketamir-2 is specifically designed to address the limitations of existing treatments through its selective targeting of the NMDA receptor. By binding to a specific site on the NMDA receptor with low affinity, Ketamir-2 significantly reduces the risk of psychotropic effects commonly associated with traditional ketamine. Furthermore, it is not a substrate for P-glycoprotein (P-gp), which allows for better oral absorption and enhanced blood-brain barrier penetration. Unlike traditional ketamine, Ketamir-2 does not cause sedation or hyperactivity-side effects often linked to psychiatric conditions such as schizophrenia, bipolar mania, and ADHD. As a non-opioid therapy, Ketamir-2 is designed to eliminate the risks of dependency and addiction. Additionally, the DEA has determined that Ketamir-2 is not a controlled substance, streamlining accessibility and minimizing regulatory hurdles.

Preclinical studies have demonstrated Ketamir-2's ability to achieve 100% pain reversal, fully normalizing pain thresholds in validated neuropathic pain models. Furthermore, Ketamir-2 has shown a strong safety and toxicological profile, observed across cardiovascular, CNS, respiratory, or toxicology assessments.

Dr. Itzchak Angel, Chief Scientific Advisor at Mira, commented: "Ketamir-2's selective mechanism of action, strong safety profile, and ability to achieve full pain reversal underscore its potential as a transformative therapy."

With the IND submitted, MIRA expects to initiate Phase I Clinical Trials in Q1 2025 to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers. Phase IIa trials are expected to follow in late 2025 to assess efficacy in neuropathic pain patients. Beyond neuropathic pain, the company is exploring additional indications for Ketamir-2, including MDD, MDD-SI, TRD and PTSD.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD).

MIRA's novel oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. If approved by the FDA, MIRA-55 could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.

The U.S. Drug Enforcement Administration's scientific review concluded that both Ketamir-2 and MIRA-55 would not be considered controlled substances or listed chemicals under the Controlled Substances Act and its governing regulations.

Additional information about MIRA Pharmaceuticals is available at www.mirapharmaceuticals.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA Pharmaceuticals' (or the "Company") management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2. Any forward-looking statements in this press release are based on the Company's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2023, and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
[email protected]
(786) 432-9792

SOURCE: Mira Pharmaceuticals, Inc.

T.Gilbert--TFWP